RochePitzer

Frank Pitzer made chief executive at NimbleGen

pharmafile | April 7, 2010 | Appointment | Research and Development NimbleGen, Roche, appointment, research and development 

Roche has promoted Dr Frank Pitzer to chief executive for its Madison, US headquartered genomics business NimbleGen.

Dr Pitzer has been with Roche for eight years, and the company said he would have instrumental role in guiding NimbleGen, a global leader in microarray tools for genetic discovery and analysis, through its next stage of growth.

He was most recently head of divisional quality and regulatory affairs at Roche Diagnostics and an active member of the Diagnostics Executive Committee.

“We are extremely excited to announce Dr Frank Pitzer as the chief executive of Roche NimbleGen and look forward to expanding the company’s position as a leading genomics solution provider,” said Manfred Baier, head of Roche Applied Science.

“Frank’s leadership skills and extensive experience in the life science industry make him the perfect fit to guide Roche NimbleGen through the next stages of growth. His valuable insight and outstanding management experience will further entrench the company as a leading manufacturer of microarray technologies.”

Related Content

Roche’s Alecensa approved by FDA as lung cancer treatment

Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …

Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment

Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has …

Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn

Lonza has announced that it has signed an agreement to acquire the Genentech large-scale biologics …

Latest content